Combinatorial immunotherapy: PD-1 may not be LAG-ing behind any more

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1172-1174

  Turnis, Meghan E ^a   Korma, Alan J ^b   Drake, Charles G ^c   Vignali, Dario A A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Biologics Discovery California   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; CD152; CD223; CD279; CTLA 4; Immunotherapy; Ipilimumab; LAG 3; Lymphocyte; MDX 1106; PD 1; Synergy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; IMMUNOLOGIC AGENT; IPILIMUMAB; LIGAND; LYMPHOCYTE ACTIVATOR GENE 3 RECEPTOR; LYMPHOCYTE ACTIVATOR GENE 3 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; PROTEIN PD L1; RADIOISOTOPE; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GRAFT; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG TOLERABILITY; EFFECTOR CELL; FIBROSARCOMA; GENE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LAG3 GENE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; METASTATIC MELANOMA; MONOTHERAPY; NONHUMAN; PDCD1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR ESCAPE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 84881141075     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20593     Document Type: Article

References (10)

1. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620.
2. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 2009; 21:1065-77; PMID:19651643; http://dx.doi.org/10.1093/intimm/dxp072.
3. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21:503-13; PMID:15485628; http://dx.doi.org/10.1016/j.immuni.2004.08.010.
4. Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005; 174:688-95; PMID:15634887.
5. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009; 182:6659-69; PMID:19454660; http://dx.doi.org/10.4049/jimmu-nol.0804211.
6. Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals J P, Baumgaertner P, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012; 7:30852; PMID:22347406; http://dx.doi.org/10.1371/journal.pone.0030852.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
8. Curran MA, Montalvo W, Yagita H, Allison J P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107.
9. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacody-namics and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609.
10. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450:566-9; PMID:18033300; http://dx.doi.org/10.1038/nature06306.